18 research outputs found
Maladie de Paget extra-mammaire associée à un carcinome indifférencié à composante neuroendocrine anal traité par anti-PD1
Traitement des carcinomes épidermoïdes cutanés métastatiques et localement avancés par cémiplimab : étude prospective monocentrique
Phase I Study of Androgen Deprivation Therapy in Combination with Anti-PD-1 in Melanoma Patients Pretreated with Anti-PD-1.
Androgen deprivation regenerates the thymus in adults, expanding of T-cell receptor V β repertoire in blood and lymphoid organs and tumor-infiltrating lymphocytes in human prostate tumors. In melanoma murine models, androgen receptor promotes metastases and androgen blockade potentiates antitumor vaccine efficacy. This phase I study evaluated the safety, efficacy, and pharmocodynamics of androgen deprivation with the gonadotropin releasing hormone (GnRH) agonist triptorelin combined with nivolumab in male patients with melanoma resistant to anti-PD-1.
Adult male patients with advanced melanoma who progressed under anti-PD-1 containing regimens received triptorelin 3.75 mg every 4 weeks, nivolumab 3 mg/kg every 2 weeks, and bicalutamide 50 mg once daily during the first 28 days. Tumor response was first assessed after 3 months; adverse events (AE) were monitored throughout the study. T-cell receptor excision circles (TREC), a biomarker of thymus activity, were explored throughout the study.
Of 14 patients, 4 were locally advanced and 10 had distant metastases. There were no grade 4 or 5 AEs. Five grade three AEs were reported in 4 patients. According to RECIST v1.1, best overall response was partial response (PR) in one patient with a pancreas metastasis, stable disease (SD) in 5 patients, and progressive disease in 8 patients. According to iRECIST, a second PR occurred after an initial pseudoprogression, TRECs increased in 2 patients, one with PR who also had an increase in TILs, and the second with SD.
This combination was well tolerated. Disease control was obtained in 42.8% (RECIST) and 50% (iRECIST). The evidence for thymus rejuvenation was limited
Usefulness of the \u2018two-step method\u2019 of digital follow-up for early-stage melanoma detection in high-risk French patients: a retrospective 4-year study
Clinical, biological and histological characteristics of bullous pemphigoid associated with anti-PD-1/PD-L1 therapy: A national retrospective study.
European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force `Dermatology for cancer patients' position statement
The introduction of immune checkpoint inhibitors (ICIs) opened a new era
in oncologic therapy. The favourable profile of ICIs in terms of
efficacy and safety can be overshadowed by the development of
immune-related adverse events (irAEs). Dermatologic irAEs (dirAEs)
appear in about 40% of patients undergoing immunotherapy and mainly
include maculopapular, psoriasiform, lichenoid and eczematous rashes,
auto-immune bullous disorders, pigmentary disorders, pruritus, oral
mucosal lesions, hair and nail changes, as well as a few rare and
potentially life-threatening toxicities. The EADV task force Dermatology
for Cancer Patients merged the clinical experience of the so-far
published data, incorporated the quantitative and qualitative
characteristics of each specific dirAEs, and released
dermatology-derived, phenotype-specific treatment recommendations for
cutaneous toxicities (including levels of evidence and grades of
recommendation). The basic principle of management is that the
interventions should be tailored to serve the equilibrium between
patients’ relief from the symptoms and signs of skin toxicity and the
preservation of an unimpeded oncologic treatment